Pfizer shares hit 52-week high as Q3 earnings report looms
The gist
Pfizer stock closed at $30.52 on Oct 30, near the top of its 52-week range, ahead of Nov 3 earnings.
Analysts are split on whether the rebound can offset falling COVID sales and patent expirations.
How it unfolded
- Oct 6, 2026Pfizer declared a fourth-quarter 2026 dividend of $0.43 per share, payable Dec 7 to shareholders of record as of Nov 6 — its 352nd consecutive quarterly dividend.
- Oct 13, 2026Guggenheim reaffirmed its Buy rating and $31 price target on Pfizer ahead of Q3 earnings, forecasting revenue of $16.16 billion and EPS of $0.77.
- Oct 28, 2026Pfizer reported topline Phase 3 results for Elrexfio (elranatamab) as a monotherapy, showing prolonged progression-free survival in relapsed/refractory multiple myeloma.